DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci | Annals of Clinical Microbiology and Antimicrobials | Full Text

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci | Annals of Clinical Microbiology and Antimicrobials | Full Text

Annals of Clinical Microbiology and Antimicrobials

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

• Carmen Hidalgo-Tenorio, 
• David Vinuesa, 
• Antonio Plata, 
• Pilar Martin Dávila, 
• Simona Iftimie, 
• Sergio Sequera, 
• Belén Loeches, 
• Luis Eduardo Lopez-Cortés, 
• Mari Carmen Fariñas, 
• Concepción Fernández-Roldan, 
• Rosario Javier-Martinez, 
• Patricia Muñoz, 
• Maria del Mar Arenas-Miras, 
• Francisco Javier Martínez-Marcos, 
• Jose Maria Miró, 
• Carmen Herrero, 
• Elena Bereciartua, 
• Samantha E. De Jesus & 
• Juan Pasquau 

Annals of Clinical Microbiology and Antimicrobials volume 18, Article number: 30 (2019) | Download Citation

Article metrics

• 28 Accesses
• 1 Altmetric
• Metricsdetails

Abstract

Objectives

To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact.

Methods

A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year.

Results

Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€).

Conclusions

DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug